Information Provided By: 
Fly News Breaks for July 15, 2019
TXMD
Jul 15, 2019 | 08:40 EDT
Jefferies analyst Chris Howerton lowered his price target for TherapeuticsMD to $3 from $4 following the company's recent 2019 guidance and clarity on Annovera. The analyst's base-case for Annovera assumes new contraceptive category status and peak estimates of 35%, $315M, and 60% for penetration, revenue and net margin, respectively. He says the guidance gives him pause and keeps a Hold rating on the shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
